In 2022, a systematic review by Joanna Moncrieff and colleagues published in Molecular Psychiatry examined the full body of evidence for the serotonin hypothesis of depression — the theory that depression is caused by a deficiency or dysregulation of serotonin in the brain, and that SSRIs work by correcting this chemical imbalance. The review’s conclusion: there is no consistent evidence that serotonin levels or serotonin activity are responsible for depression. The serotonin hypothesis, as a causal explanation for depression, is not supported by the evidence.
This is not a fringe finding. It was published in a peer-reviewed journal by researchers at University College London. It is significant not because it means antidepressants do not work for anyone — some people do report meaningful benefit — but because the theoretical foundation that justified prescribing SSRIs to hundreds of millions of people globally, and that was used to tell patients their brains had a chemical imbalance requiring a lifetime of medication, was not what the evidence actually showed.
Important: Abruptly stopping antidepressants is medically dangerous. If you take antidepressants, do not stop suddenly. Discontinuation must be done slowly and with medical guidance. This post is about informed consent — understanding what you were or were not told before you started — not about stopping.
THE PUBLICATION BIAS — WHAT THE RESEARCH ACTUALLY SHOWED
In 2008, Erick Turner and colleagues published a landmark analysis in the New England Journal of Medicine examining FDA trial data for 12 antidepressants. Of 74 clinical trials registered with the FDA, 38 showed positive results and 36 showed negative or questionable results. Of the 38 positive trials, 37 were published. Of the 36 negative trials, only 3 were published — the rest were either unpublished or published in a way that presented negative results as positive. When only published literature was analyzed, 94% of trials appeared positive. When all trial data including unpublished studies was analyzed, only 51% were positive.
Irving Kirsch’s meta-analysis, published in PLOS Medicine in 2008, analyzed all FDA trial data including unpublished studies for six antidepressants. The conclusion: the difference between antidepressants and placebo was statistically significant but clinically marginal for most patients — below the threshold that the National Institute for Clinical Excellence in the UK uses to define a meaningful clinical difference. The drugs outperformed placebo significantly only in patients with the most severe depression. For mild to moderate depression — the majority of cases for which antidepressants are prescribed — the clinical benefit over placebo was minimal.
SIDE EFFECTS THAT ARE UNDERREPORTED
Emotional blunting: A majority of SSRI users in survey research report a subjective experience described as emotional numbing — a reduction in the full range of emotional experience, not just negative emotions but positive ones too. Joy, love, enthusiasm, motivation, and the capacity for deep feeling are reduced. This is distinct from the intended therapeutic effect and is one of the most commonly reported reasons for discontinuing antidepressants. Many patients describe losing their personality or becoming a different person. Civic Hush captured it precisely: yellow pills that wiped the fire from her face.
Sexual dysfunction: SSRIs and SNRIs cause sexual side effects in 30-70% of users — reduced libido, anorgasmia, delayed ejaculation, and genital numbness. These are often permanent or long-lasting in a documented subset of patients — a condition called Post-SSRI Sexual Dysfunction (PSSD) — that persists after the drug is stopped. PSSD was added to EU regulatory labeling in 2019. It is rarely mentioned at prescribing and frequently dismissed when patients report it.
Increased suicide risk in adolescents: The FDA’s black box warning on antidepressants — added in 2004 — warns of increased suicidal thinking and behavior in children, adolescents, and young adults up to age 24. This warning exists because clinical trial data showed increased suicidality in this age group on antidepressants compared to placebo. Prescribers are required to discuss this warning and often do not.
Weight gain and metabolic effects: Long-term SSRI use is associated with weight gain, insulin resistance, and metabolic changes. These are often misattributed to the underlying depression rather than the treatment.
DISCONTINUATION SYNDROME — THE WITHDRAWAL CALLED RELAPSE
When patients attempt to stop antidepressants, many experience a cluster of symptoms: dizziness, electric shock sensations (called brain zaps), irritability, insomnia, flu-like feelings, intense anxiety, and the return of depressive symptoms. These symptoms were called “discontinuation syndrome” by pharmaceutical companies — deliberately distinct from the word “withdrawal,” which implies dependency. The framing served a purpose: withdrawal implies the drug created a dependency. Discontinuation syndrome implies the symptoms are simply a consequence of stopping.
The return of depressive symptoms during discontinuation was — and in many clinical settings still is — interpreted as evidence that the patient’s depression has returned and they need to stay on the medication. In many cases, what is being observed is withdrawal, not relapse. The pharmaceutical industry’s framing, and the incentive structures of psychiatric practice, tended toward interpreting the ambiguity as relapse requiring continued or resumed medication.
A 2019 Royal College of Psychiatrists report acknowledged that antidepressant withdrawal symptoms can be severe and long-lasting, affecting a significant minority of patients, and that previous clinical guidance had significantly underestimated how difficult discontinuation could be. Tapering off antidepressants should be done very slowly, over months to years in some cases, with dose reductions of 5-10% at a time. The hyperbolic taper approach, developed by researchers including Mark Horowitz, accounts for the non-linear way serotonin receptor occupancy responds to dose changes and results in significantly fewer withdrawal symptoms than standard taper schedules.
WHERE THE RESEARCH IS ACTUALLY GOING
If the serotonin hypothesis is not the explanation for depression, what is? The emerging research points in several directions. The gut-brain axis — the bidirectional communication between the gut microbiome and the brain via the vagus nerve, immune signaling, and neurotransmitter production — is increasingly central to depression research. The gut produces approximately 90% of the body’s serotonin. Gut microbiome diversity is significantly lower in people with depression than in controls. Fecal microbiota transplant studies have transferred depressive behavior between animals by transferring gut bacteria.
Chronic inflammation is another emerging central mechanism. C-reactive protein and other inflammatory markers are consistently elevated in people with depression. Anti-inflammatory interventions — dietary change, omega-3 supplementation, exercise — show antidepressant effects in multiple studies, particularly in people with elevated inflammatory markers.
SUPPORTING YOUR BODY AND MIND
Exercise: The most robust non-pharmaceutical antidepressant with the largest evidence base. Multiple meta-analyses find exercise comparable to antidepressants for mild to moderate depression, with benefits that persist after the intervention ends. The mechanism involves BDNF (brain-derived neurotrophic factor), dopamine and serotonin modulation, inflammation reduction, and HPA axis regulation.
St. John’s Wort (Hypericum perforatum): The most extensively studied herbal antidepressant. Multiple meta-analyses find it superior to placebo and comparable to SSRIs for mild to moderate depression, with fewer side effects. Significant drug interactions — it induces CYP450 enzymes and reduces the effectiveness of many medications including hormonal contraceptives. Should not be combined with SSRIs due to serotonin syndrome risk. Not appropriate for severe depression. The evidence for mild to moderate depression is genuine and substantially stronger than its reputation in conventional medicine suggests.
Gut microbiome support: Fermented foods, prebiotic fiber, and microbiome diversity support are directly relevant given the gut-brain axis evidence.
Omega-3 fatty acids: EPA specifically has documented antidepressant effects in multiple clinical trials, particularly in people with elevated inflammatory markers. Fatty fish, walnuts, and flaxseed are dietary sources. High-dose fish oil with a high EPA:DHA ratio is the supplement form with the most evidence.
Saffron: Multiple randomized controlled trials find saffron extract (30mg/day of standardized extract) comparable to SSRIs for mild to moderate depression with fewer side effects. The active compounds crocin and safranal appear to modulate serotonin reuptake and have anti-inflammatory and antioxidant properties. A culinary herb with genuine clinical evidence.
Cross-reference: Know Your Medication — Building Your Protocol | Know Your Body | Herbal Remedies | Flora Archive | Root Cellar
FROM THE BUNKER
White Coats in the Smoke — Civic Hush
“They gave my mama yellow pills / to quiet nerves and soften wills / they called it care they called it grace / but it wiped the fire from her face.”
Civic Hush named what the clinical literature calls emotional blunting. The fire that goes out when the pills quiet everything — including the parts worth keeping.
Listen on KaNafia
FROM THE WASTELAND
Leaf Juice — Wasteland Survival Series, Book 1
St. John’s Wort, saffron, and the nervine and adaptogenic herbs relevant to mood and nervous system support have preparation protocols in Leaf Juice as teas, tinctures, and tonics.
Paperback | Kindle